WO2015178700A1 - Composition anti-virale comprenant un produit de la fermentation de fruits du genre citrus utilisé comme principe actif - Google Patents

Composition anti-virale comprenant un produit de la fermentation de fruits du genre citrus utilisé comme principe actif Download PDF

Info

Publication number
WO2015178700A1
WO2015178700A1 PCT/KR2015/005110 KR2015005110W WO2015178700A1 WO 2015178700 A1 WO2015178700 A1 WO 2015178700A1 KR 2015005110 W KR2015005110 W KR 2015005110W WO 2015178700 A1 WO2015178700 A1 WO 2015178700A1
Authority
WO
WIPO (PCT)
Prior art keywords
fruit
citrus
fermentation
composition
virus
Prior art date
Application number
PCT/KR2015/005110
Other languages
English (en)
Korean (ko)
Inventor
조주현
권두한
백순옥
박인재
오세량
최구희
윤지현
박성환
장미진
Original Assignee
(주) 휴럼
한국생명공학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주) 휴럼, 한국생명공학연구원 filed Critical (주) 휴럼
Publication of WO2015178700A1 publication Critical patent/WO2015178700A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon

Definitions

  • the present invention relates to a composition for the prevention and treatment of viral diseases comprising bilberry fruit fermentation as an active ingredient.
  • the present invention relates to a composition for the prevention and treatment of a disease infected by one or more viruses selected from the group consisting of influenza viruses, a disease infected by a rotavirus, or a disease infected by a corona virus.
  • Influenza virus is a genome-based virus belonging to the orthomyxoviridae family, and when infected, causes severe respiratory distress.
  • Influenza viruses are divided into types A, B, and C, of which A and B are frequently infected with humans.
  • serotypes of type A viruses are determined by differences in the amino acid sequence of hemagglutinin and neuraminidase proteins.
  • Hemagglutinin (H) of influenza A virus has 16 different subtypes and neuraminidase enzyme (N) has 9 different subtypes. How is the combination of hemagglutinin protein and neuraminidase protein subtypes made? The new variant is determined.
  • influenza virus vaccines also include H1N1 and H3N2 influenza viruses and type B influenza viruses of type A together.
  • influenza virus is an RNA virus with a high incidence of genotyping, even the same H1N1 virus may have low efficacy against the vaccine.
  • Janamivir and oseamimivir are used as therapeutic agents for influenza virus as drugs that inhibit the function of neuraminidase enzyme of influenza virus (Dreitlein WB., Maratos J., Brocavich. 2001, Clin Ther , 23: 327-355).
  • Ginamivir is sold under the trademark Relenza by Glaxowelcome Inc. and is inhaled to inhale medicine powder through the nose.
  • the oseltamivir is sold under the name Tamiflu by Roche, and is used as an oral medication such as amantadine.
  • the rerenza may have trouble breathing and asthma is likely to worsen, and Tamiflu has side effects such as nausea and vomiting (McNicholl and McNicholl, 2001, Ann. Pharmacother. 35 (1): 57- 70) Efficacy varies greatly depending on the type of influenza virus.
  • ribavirin is a drug that inhibits the growth of influenza virus and is applied to both DNA and RNA virus infections (Magden J et al., 2005, Appl Microbiol Biotechnol., 66 (6): 612-621 ).
  • ribavirin also causes serious side effects such as anemia (Soriano V et al., 6, 2011, J Antimicrob Chemother, 66 (8): 1673-1686).
  • Corta virus is a genome of RNA that belongs to the family of coronaviridae, and when infected, causes respiratory disease or severe enteritis.
  • the corona virus is spread to the air or feces and has the characteristic that the onset of the disease varies depending on the animal.
  • respiratory diseases such as SARS and cold are caused.
  • pigs and dogs it causes severe enteritis, cats cause severe peritonitis, and rats cause hepatitis.
  • vaccines there is no antiviral treatment for coronavirus infection, and there are no vaccines except for some swine coronaviruses, and the swine coronaviruses in which the vaccines are developed also have low vaccine efficacy due to the high frequency of viral variants.
  • rotavirus is a genome-based virus belonging to the genus Reoviridae, which causes severe enteritis.
  • Rotavirus is the most common cause of gastroenteritis in infants and is spread by feces or oral and causes symptoms such as vomiting, diarrhea, fever and abdominal pain. There is no antiviral treatment for rotavirus infection, and rotavirus vaccination is not included in national vaccination items. Rotavirus vaccines have live oral vaccines, but rotaviruses do not have significant preventive effects due to the presence of subgroups and various serotypes.
  • Citrus fruits are used for food as a fruit of the tree belonging to the genus citrus , and are used as juices to make juices and are sold as beverages.
  • citrus fruits are in high demand.
  • the industrial value of citrus fruits is stagnant, so it is necessary to create nutritional value for citrus fruits or create new value as favorite beverage and other functional foods.
  • the present inventors showed low antiviral ability in the citrus juice, but the present invention was completed by confirming that the citrus juice was inoculated with Bacillus bacterium and fermented to have an excellent antiviral activity against influenza virus. It was.
  • An object of the present invention is to provide a pharmaceutical composition for the prevention and treatment of viral diseases containing a fermented product inoculated with Bacillus bacteria in a citrus fruit (Citrus) fruit grinding liquid as an active ingredient.
  • Another object of the present invention is to provide a fermented product fermented by inoculating Bacillus bacteria to bilberry fruit pulverized liquid as a health food for improving health against viral infectious diseases.
  • Another object of the present invention to provide a feed additive for the prevention and improvement of livestock virus infectious diseases containing a fermented product inoculated and fermented Bacillus bacteria in the bilberry fruit juice.
  • the present invention provides a pharmaceutical composition for the prevention and treatment of viral diseases containing a fermented product inoculated and fermented by Bacillus bacteria in pulverine fruit juice (crushed).
  • the present invention provides a health food for improving the health of the virus-infected diseases fermented by inoculating Bacillus bacteria in the citrus fruit juice.
  • the present invention provides a feed additive for the prevention and improvement of livestock virus infectious diseases containing a fermented product inoculated with Bacillus bacteria in a citrus fruit pulverized liquid as an active ingredient.
  • Fermented product of the genus citrus fruit pulverized liquid (grind) of the present invention with Bacillus bacterium has no human toxicity and exhibits a proliferation inhibitory effect against influenza virus, and thus, is a pharmaceutical composition for antiviral and health food. And it can be usefully used as an active ingredient of feed additives.
  • the fermented product of the genus citrus fruit grinding liquid of the present invention fermented with Bacillus bacteria shows an inhibitory effect on the growth of corona virus, as an active ingredient of antiviral pharmaceutical composition, health food and feed additives. It can be usefully used.
  • the fermented product fermented with the genus citrus fruit pulverized liquid of the present invention Bacillus bacteria exhibits a proliferation inhibitory effect on rotavirus, as an active ingredient of antiviral pharmaceutical composition, health food and feed additives It may be useful.
  • H1N1 is a diagram confirming the antiviral ability against the influenza A virus (H1N1) of the fermented product inoculated with Bacillus bacteria (KJ000007) in the citrus fruit juice.
  • Figure 2 is a diagram confirming the antiviral ability against the influenza A virus (A / WS / 33) of the fermentation of fermented by inoculating Bacillus bacteria (KJ000007) in the citrus fruit juice.
  • Figure 3 is a diagram confirming the antiviral ability against influenza B virus fermented by inoculating Bacillus bacteria (KJ000007) in the citrus fruit juice.
  • FIG. 4 is a diagram comparing the antiviral ability of the fermented corona virus inoculated with Bacillus bacteria (KJ0000007) in the citrus fruit pulverized liquid by the concentration of the antiviral ability of ribavirin and fruit pulverized liquid.
  • FIG. 5 is a diagram showing the maximum antiviral activity against the corona virus of citrus fermentation products (fermentation product fermented by inoculating Bacillus bacteria (KJ000007) in citrus fruit juice) and ribavirin, citrus fruit juice.
  • Figure 6 is a diagram confirming the antiviral ability against human rotavirus fermented by inoculating Bacillus bacteria in bilberry fruit juice.
  • Figure 7 is a diagram confirming the antiviral activity against the pig rotavirus fermented by inoculating Bacillus bacteria in bilberry fruit juice.
  • Figure 8 is a diagram confirming the antiviral ability against bovine rotavirus fermented by inoculating Bacillus bacteria in bilberry fruit juice.
  • the present invention provides a pharmaceutical composition for the prevention and treatment of viral diseases containing a fermented product inoculated with Bacillus bacteria in a citrus fruit pulverized liquid (grind) as an active ingredient.
  • the citrus fruit is most preferably selected as a citrus fruit of the citrus tree, but not limited thereto, and any fruit belonging to the citrus tree may be used.
  • the viral diseases include, but are not limited to, diseases infected by influenza virus, diseases infected by corona virus, and diseases infected by rotavirus.
  • the inventors have produced bilberry fruit fermentation.
  • the present inventors confirmed the antiviral activity of the citrus fruit fermentation using influenza A virus (N1H1 type) and influenza B virus, the antiviral activity was significantly increased in the fermented product than the citrus juice, the fermentation product It showed antiviral activity comparable to Tamiflu used as a positive control (see Fig. 1).
  • the present inventors confirmed the antiviral activity of the citrus fruit fermentation using corona virus, the antiviral activity was significantly increased in the fermented product than the citrus juice, the fermented product is comparable to ribavirin used as a positive control group It showed antiviral activity (see FIG. 4).
  • the present inventors confirmed the antiviral activity of citrus fruit fermentation using human rotavirus, porcine rotavirus, and bovine rotavirus. As a result, the antiviral activity was significantly increased in the fermented product than the citrus juice. Antiviral activity was comparable to that of ribavirin used as a positive control (see FIG. 7).
  • the citrus fruit fermentation product of the present invention has no toxicity and is safe for the human body, and has an antiviral effect because it has a proliferation inhibitory effect against influenza virus, a proliferation inhibitory effect against coronavirus, and a proliferation inhibitory effect against rotavirus. It has been confirmed that it can be usefully used as a pharmaceutical composition.
  • composition containing (including) the citrus fruit fermentation product of the present invention may further contain one or more active ingredients exhibiting the same or similar functions in addition to the above components.
  • a pharmaceutically acceptable salt thereof may be added to the citrus fruit fermentation, and the salt may be an acid addition salt formed by a pharmaceutically acceptable free acid. useful.
  • the active ingredient of the composition can form a pharmaceutically acceptable acid addition salt according to a conventional method in the art.
  • the inorganic acid and organic acid may be used as the free acid, and hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, etc. may be used as the inorganic acid, and citric acid, acetic acid, lactic acid, tartaric acid, maleic acid, Fumaric acid, formic acid, propionic acid, oxalic acid, trifluoroacetic acid, benzoic acid, gluconic acid, methanesulfonic acid, glycolic acid, succinic acid, 4-toluenesulfonic acid, galluxuronic acid, embonic acid, glutamic acid or aspartic acid May be used, but is not limited thereto.
  • composition of the present invention may further comprise a pharmaceutically acceptable additive, wherein the pharmaceutically acceptable additives include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose , Mannitol, malt, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, opiodry, sodium starch glycolate, lead carnauba, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate , Sucrose, dextrose, sorbitol, talc and the like can be used.
  • the pharmaceutically acceptable additives include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose , Mannitol, malt, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxyprop
  • the pharmaceutically acceptable additive according to the present invention is preferably included 0.1 to 90 parts by weight (%) based on the total weight (%) of the composition, but is not limited thereto.
  • composition of the present invention can be administered in various oral and parenteral formulations during actual clinical administration, and when formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc., which are commonly used It can be prepared using.
  • diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc., which are commonly used It can be prepared using.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate, It may be prepared by mixing sucrose, lactose or gelatin.
  • lubricants such as magnesium styrate talc may also be used.
  • Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents, water and liquid paraffin. .
  • Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • witepsol macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • composition of the present invention can be administered orally or parenterally according to the desired method, external or intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection or intrathoracic injection during parenteral administration It is desirable to choose an injection method.
  • Dosage varies depending on the patient's weight, age, sex, health condition, diet, time of administration, method of administration, rate of excretion and severity of disease.
  • Dosage units may contain, for example, one, two, three or four times the individual dosage, or they may contain 1/2, 1/3 or 1/4 times.
  • Individual dosages specifically contain amounts in which the effective drug is administered at one time, which typically corresponds to all, 1/2, 1/3 or 1/4 times the daily dose.
  • the effective dose of the composition of the present invention may be 0.0001 to 10 g / kg, specifically 0.001 to 1 g / kg, it may be administered 1 to 6 times a day.
  • the dosage may be increased or decreased depending on the route of administration, the severity of the disease, sex, weight, age, etc., and the above dosage does not limit the scope of the present invention in any way.
  • the present invention provides a health food for the prevention and improvement of viral diseases containing bilberry fruit fermentation as an active ingredient.
  • the citrus fruit is most preferably selected as a citrus fruit, but not limited to this, any fruit belonging to the citrus can be used.
  • the fermented product was prepared using Bacillus bacteria ( Bacillus substilis, NCBI Accession No. KJ000007) in citrus fruits, but is preferably prepared by inoculation of Bacillus bacteria ( Bacillus substilis ) in citrus fruits, but is not limited thereto.
  • Bacillus bacteria Bacillus substilis, NCBI Accession No. KJ000007
  • in the production of the fermentation in the preferred embodiment of the present invention was prepared using the US Biotechnology Information Center (NCBI) Accession No. KJ000007, but not limited to Bacillus supstilis .
  • the viral disease includes, for example, a disease infected by at least one influenza virus selected from the group consisting of influenza viruses, a disease infected by corona virus, and a disease infected by rotavirus.
  • a disease infected by at least one influenza virus selected from the group consisting of influenza viruses, a disease infected by corona virus, and a disease infected by rotavirus.
  • the health food of the present invention may be added with the bilberry fruit fermentation as it is, or may be used with other food or food ingredients, and may be appropriately used according to a conventional method.
  • Examples of foods to which the citrus fruit fermentation may be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, beverages, Tea, drink, alcoholic beverages and vitamin complexes, etc., and includes all of the health food in the usual sense.
  • the health beverage composition of the present invention may contain various flavors or natural carbohydrates, etc. as additional components, as in the general beverage.
  • the above-mentioned natural carbohydrates are glucose, monosaccharides such as fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol and erythritol.
  • sweetening agent natural sweetening agents such as taumartin, stevia grinding liquid, synthetic sweetening agents such as saccharin, aspartame, and the like can be used.
  • the ratio of the natural carbohydrate is generally about 0.01 to 0.04 weight (g), preferably about 0.02 to 0.03 weight (g) per 100 weight (g) of the composition of the present invention.
  • the health food of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol And carbonation agents used in carbonated beverages.
  • Others may contain pulp for the production of natural fruit juices, fruit juice drinks and vegetable drinks.
  • the proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 weight (%) per 100 weight (%) of the composition of the present invention.
  • the present invention also provides a feed additive containing bilberry fruit fermentation as an active ingredient.
  • the citrus fruit is most preferably selected from the group consisting of citrus fruits, not limited to this, any fruit belonging to the citrus can be used.
  • Bacillus bacteria in the preferred embodiment of the present invention was prepared using Bacillus bacteria, the US Biotechnology Information Center (NCBI) accession number (KJ000007), but not limited to Bacillus bacteria ( Bacillus substilis ).
  • the viral disease includes, for example, a disease infected by one or more viruses selected from the group consisting of influenza viruses, a disease infected by a corona virus, and a disease infected by a rotavirus. It is not limited to this.
  • Citrus fruit fermentation of the present invention is composed of 0.01 to 1% by weight relative to 100% (%) of the feed to be added, preferably citrus fruit fermentation is composed of 0.05 to 0.5% by weight (%) Most preferably, the bilberry fruit fermentation is 0.12 weight (%).
  • the feed additive may additionally contain a carrier that is acceptable to a unit animal.
  • the feed additive may be added as it is, or a known carrier, stabilizer, or the like, and various nutrients such as vitamins, amino acids, minerals, antioxidants and other additives may be added, if necessary. It may be in a suitable state such as powder, granules, pellets, suspensions and the like.
  • the unit animal may be supplied alone or mixed with feed.
  • Tamiflu and ribovarin, test compounds were purchased from Roche and Sigma, respectively.
  • the virus used in the present invention includes two types of influenza type A virus H1N1 type (A / PR / 8/34, A / WS / 33) and influenza type B virus (B / Lee / 40). ), The virus activity was cultured and measured, and then stored at -70 ° C for use.
  • Ribavirin a test compound, was purchased from Sigma.
  • the corona virus used in the present invention was supplied with corona virus (PEDV, porcine epidemic diarrhea virus) from the Ministry of Agriculture, Forestry and Livestock Quarantine and was stored at -70 ° C after culturing the virus activity.
  • PEDV porcine epidemic diarrhea virus
  • Ribavirin the test compound, It was purchased from Sigma.
  • the viruses used in the present invention were three types of rotaviruses, and human rotaviruses were distributed from the American Cell Line Bank (ATCC), and swine rotaviruses and bovine rotaviruses were distributed from the Ministry of Agriculture, Forestry and Livestock Quarantine Headquarters, and then cultured and measured. , Stored at -70 °C was used.
  • ATCC American Cell Line Bank
  • swine rotaviruses and bovine rotaviruses were distributed from the Ministry of Agriculture, Forestry and Livestock Quarantine Headquarters, and then cultured and measured. , Stored at -70 °C was used.
  • citrus fruits were first prepared.
  • the powder was dissolved in dimethylsulfoxide and used at a concentration of 100 mg / mL.
  • Bacillus substilus Bacillus substilus.
  • Bacteria US National Biotechnology Information Center Accession No. KJ000007
  • the inhibitory effect on the influenza A virus of the bilberry fruit ferment prepared by the method of Example 1 was confirmed using MDCK cell line, which is a dog kidney cell-derived cell line.
  • the method for measuring the virus growth inhibitory ability of the citrus fruit pulverized liquid and the fermented product is two types of influenza virus type A, H1N1 (A / PR / 8 / 34) and (A / WS / 33) were measured for the effect of inhibiting viral activity, respectively.
  • MDCK cells were incubated in each well of a 96-well microplate until the bottom was full of cells, then the existing culture was removed and each well was washed twice with phosphate buffer.
  • influenza virus solution adjusted to the concentration of TCID25 was added to each of the wells, and the bilberry fruit fermentation product and existing anti-influenza virus agents Tamiflu (Roche) and ribavirin (Sigma) were respectively added to dimethyl sulfoxide. It was used by dissolving.
  • the control group (Tamiflu, ribavirin) was administered to each well at a final concentration of 0.1 ⁇ 100 ⁇ g / ml, bilberry fruit fermentation was administered to each well at a final concentration of 1 ⁇ 1000 ⁇ g / ml, 48 hours after incubation The infection experiment was terminated, 70% acetone was added to each well by 100 ul, then left at -20 ° C for 1 hour, and dried in a drier.
  • the dried product was stained for 30 minutes by adding 100 ul of 0.4% (w / v) SRB (sulforhodamine B) solution dissolved in 1% (v / v) acetic acid, and 1% (v / v) washed four times with acetic acid and dried. Again 100 ul of 10 mM Tris solution (pH 10.5) was added to the well plate to dissolve the dye bound to the cells and the absorbance was measured at 562 nm.
  • the statistics for the results are expressed as the mean value and the standard deviation of the values of three experiments under the same conditions.
  • the maximum antiviral activity of Tamiflu against influenza A virus was 79.70 ⁇ 4.63% at a concentration of 100 ⁇ g / ml, and the maximum antiviral activity of citrus juice was 1000. 12.98 ⁇ 12.55% at the concentration of ⁇ g / ml, respectively.
  • the maximum antiviral activity of citrus ferment was 50.42 ⁇ 11.15% at the concentration of 1000 ⁇ g / ml.
  • the maximum antiviral activity of Tamiflu against another influenza A virus is 19.08 ⁇ 14.35% at a concentration of 100 ⁇ g / ml and ribavirin is 100 ⁇ g / ml as shown in FIG. 2.
  • the concentration was 68.74 ⁇ 8.48%.
  • the maximum antiviral activity of the citrus fruits was 0.58 ⁇ 10.32% at a concentration of 1000 ⁇ g / ml.
  • the citrus fermented product showed much higher antiviral activity than the ground liquid.
  • the maximum antiviral activity of Tamiflu against influenza B virus was 1.22 ⁇ 13.13% at a concentration of 100 ⁇ g / ml, and ribavirin at 52.36 ⁇ 5.82% at a concentration of 100 ⁇ g / ml. It was.
  • the maximum antiviral activity of citrus pulverized liquid was 9.53 ⁇ 1.40% in the concentration range of 1 ⁇ 1000 ⁇ g / ml.
  • the maximum antiviral activity of citrus ferment was 46.22 ⁇ 14.96% at the concentration of 1000 ⁇ g / ml.
  • the proliferation inhibitory effect on the corona virus of the bilberry fruit fermentation prepared by the method of Example 1 was confirmed using a Vero cell line, a monkey kidney cell-derived cell line.
  • the method for measuring the virus growth inhibition ability of the citrus fruit pulverized liquid and the fermented product was measured by the virus activity inhibitory effect on the human corona virus purchased from ATCC according to the method of (KR) 682069.
  • MA104 cells were incubated in each well of a 96-well microplate until the bottom was full of cells, then the existing culture was removed and each well was washed twice with phosphate buffer.
  • an influenza virus solution adjusted to the concentration of TCID25 was added to each of the wells, and the bilberry fruit fermentation product and the existing antiviral agent ribavirin (Sigma) were dissolved in dimethyl sulfoxide, respectively.
  • the control (ribavirin) was administered to each well at a final concentration of 0.1 ⁇ 100 ⁇ g / ml, bilberry fruit fermentation was administered to each well at a final concentration of 1 ⁇ 1000 ⁇ g / ml, 48 hours after the culture After the addition of 100 ul of 70% acetone to each well, it was left at -20 °C for 1 hour, and dried in a dryer.
  • the dried product was stained for 30 minutes by adding 100 ul of 0.4% (w / v) SRB (sulforhodamine B) solution dissolved in 1% (v / v) acetic acid, and 1% (v / v) washed four times with acetic acid and dried.
  • the statistics for the results are expressed as the mean value and the standard deviation of the values of three experiments under the same conditions.
  • the maximum antiviral activity of ribavirin against coronavirus was 66.56 ⁇ 9.44% at a concentration of 100 ⁇ g / ml
  • the maximum antiviral activity of citrus pulverized solution was 1000 ⁇ g / ml.
  • the maximum antiviral activity of citrus ferment was 100.22 ⁇ 38.56% at a concentration of 1000 ⁇ g / ml.
  • the citrus fermentation composition according to the present invention exhibits excellent antiviral activity against coronaviruses, and has a very high utility in preventing and treating coronavirus infections in industries such as medicine, food, and feed.
  • the inhibitory effect on the influenza A virus of the bilberry fruit ferment prepared by the method of Example 1 was confirmed using a MA104 cell line, which is a monkey kidney cell-derived cell line.
  • the method for measuring the virus growth inhibition ability of the citrus fruit pulverized liquid and the fermented product measured the virus activity inhibitory effect on the human rotavirus purchased from ATCC according to the method of (KR) 662069.
  • MA104 cells were incubated in each well of a 96-well microplate until the bottom was full of cells, then the existing culture was removed and each well was washed twice with phosphate buffer.
  • an influenza virus solution adjusted to the concentration of TCID25 was added to each of the wells, and the bilberry fruit fermentation product and the existing antiviral agent ribavirin (Sigma) were dissolved in dimethyl sulfoxide, respectively.
  • the control (ribavirin) was administered to each well at a final concentration of 0.1 ⁇ 100 ⁇ g / ml, bilberry fruit fermentation was administered to each well at a final concentration of 1 ⁇ 1000 ⁇ g / mL, 48 hours after the infection test After the addition of 100ul of 70% acetone to each well, it was left at -20 °C for 1 hour, and dried in a dryer.
  • the dried product was stained for 30 minutes by adding 100 ul of 0.4% (w / v) SRB (sulforhodamine B) solution dissolved in 1% (v / v) acetic acid, and 1% (v / v) washed four times with acetic acid and dried.
  • the statistics for the results are expressed as the mean value and the standard deviation of the values of three experiments under the same conditions.
  • the maximum antiviral activity of ribavirin against human rotavirus was 50.44 ⁇ 6.88% at a concentration of 100 ⁇ g / ml
  • the maximum antiviral activity of citrus juice was 1000 ⁇ g / ml.
  • the concentrations were 7.86 66.81% respectively.
  • the maximum antiviral activity of citrus ferment was 72.60 ⁇ 4.67% at the concentration of 1000 ⁇ g / ml.
  • Bacillus substilus Bacillus substilus.
  • Bacteria US National Biotechnology Information Center Accession No. KJ000007
  • the antiviral activity was increased by 9 times or more. Can be.
  • Example 4 In order to measure the effect of inhibiting proliferation against the influenza B virus of the tangerine fruit pulverized liquid prepared by the method of Example 1 and the fermented product, it was carried out by the ⁇ 4-1> method of Example 4.
  • the method for measuring the virus growth inhibition ability of the citrus fruit pulverized liquid and the fermented product measured the virus activity inhibitory effect on the swine rotavirus distributed by the Agriculture, Forestry and Livestock Quarantine Headquarters according to the method of (KR) Patent No. 682069.
  • ribavirin to porcine rotavirus showed 50.44 ⁇ 6.88% at a concentration of 100 ⁇ g / ml.
  • the maximum antiviral activity of citrus juice It showed 7.25 ⁇ 2.14% in the concentration range of 1 ⁇ 1000 ⁇ g / ml.
  • the maximum antiviral activity of citrus ferment was 61.30 ⁇ 2.17% at the concentration of 1000 ⁇ g / ml.
  • the method for measuring the virus growth inhibition ability of the citrus fruit pulverized liquid and the fermented product was measured the effect of inhibiting the virus activity against bovine rota virus distributed by the Ministry of Agriculture, Forestry and Livestock Quarantine based on the method of (KR) Patent No. 682069.
  • ribavirin against bovine rotavirus showed 71.50 ⁇ 0.88% at a concentration of 100 ⁇ g / ml.
  • the maximum antiviral activity of citrus pulverized liquid was 27.33 ⁇ 9.61% in the concentration range of 1-1000 ⁇ g / ml.
  • the maximum antiviral activity of citrus ferment was 64.18 ⁇ 6.37% at the concentration of 1000 ⁇ g / ml.
  • the citrus fermentation composition according to the present invention exhibits excellent antiviral activity against rotavirus.
  • tablets were prepared by tableting according to a conventional method for producing tablets.
  • the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.
  • 0.5 to 5.0 weight percent of the bilberry fruit fermentation product of the present invention was added to the flour and the mixture was used to prepare bread, cake, cookies, crackers and noodles.
  • 0.1-5.0 weight (%) of the citrus fruit fermentation product of the present invention was added to the soup and the juice, based on the total weight (%), to prepare the health-producing meat products, the soup of the noodles, and the juice.
  • Health weight ground beef was prepared by adding 10 weight% (%) of the bilberry fruit fermentation of the present invention to the ground weight (%).
  • Brown rice, barley, glutinous rice, and yulmu were alphad by a known method, and then dried and roasted to prepare a powder having a particle size of 60 mesh.
  • Black beans, black sesame seeds, and perilla were also steamed and dried by a known method, and then ground to a powder having a particle size of 60 mesh.
  • the tangerine fruit fermentation product of the present invention was concentrated under reduced pressure in a vacuum concentrator, and the dried product obtained by drying with a spray and a hot air dryer was pulverized to a particle size of 60 mesh by a grinder to obtain a dry powder.
  • the grains, seeds and the bilberry fruit fermentation of the present invention prepared in the above were formulated in the following ratio.
  • 1 g of the bilberry fruit fermentation of the present invention was added to 1,000 ml of apple or grape juice to prepare a fruit juice.
  • Vitamin E 0.01-0.1 weight (%)
  • Fermented product obtained by fermenting genus citrus fruit pulverized liquid (grind) with Bacillus bacterium has no human toxicity and shows a proliferation inhibitory effect against influenza virus, corona virus and rotavirus, In addition, it may be widely used as an active ingredient in health food and feed additives.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition anti-virale comprenant un produit de la fermentation de fruits du genre Citrus utilisé comme principe actif. Plus particulièrement, le produit de la fermentation de fruits du genre Citrus selon la présente invention n'est pas toxique pour le corps humain et présente un excellent effet inhibiteur sur la prolifération de divers types de virus de la grippe, et peut donc être utilisé comme composition pharmaceutique présentant une activité anti-virale, ou comme aliment santé et additif alimentaire à cette fin.
PCT/KR2015/005110 2014-05-21 2015-05-21 Composition anti-virale comprenant un produit de la fermentation de fruits du genre citrus utilisé comme principe actif WO2015178700A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2014-0061036 2014-05-21
KR1020140061036A KR101706981B1 (ko) 2014-05-21 2014-05-21 귤나무속 열매 발효물을 유효성분으로 포함하는 항바이러스용 조성물

Publications (1)

Publication Number Publication Date
WO2015178700A1 true WO2015178700A1 (fr) 2015-11-26

Family

ID=54554295

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/005110 WO2015178700A1 (fr) 2014-05-21 2015-05-21 Composition anti-virale comprenant un produit de la fermentation de fruits du genre citrus utilisé comme principe actif

Country Status (2)

Country Link
KR (1) KR101706981B1 (fr)
WO (1) WO2015178700A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001278798A (ja) * 2000-03-30 2001-10-10 Kobayashi Pharmaceut Co Ltd 抗う蝕剤
KR101068151B1 (ko) * 2008-08-22 2011-09-27 주식회사 마크로케어 항균 및 방부 활성을 갖는 식물 추출물을 포함하는 조성물 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100381736B1 (ko) 2001-03-02 2003-04-26 연성찬 모돈과 자돈의 수유 및 포유행동 제어를 위한 사운드장치
KR100418335B1 (ko) 2001-12-31 2004-02-14 김세재 감귤 발효액과 그것을 함유한 장류와 그 제조방법
KR101301971B1 (ko) 2011-09-30 2013-08-30 한국식품연구원 감귤과피 추출물 또는 나리루틴을 유효성분으로 포함하는 간기능 저해 억제용 조성물 및 감귤과피로부터 나리루틴을 추출하는 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001278798A (ja) * 2000-03-30 2001-10-10 Kobayashi Pharmaceut Co Ltd 抗う蝕剤
KR101068151B1 (ko) * 2008-08-22 2011-09-27 주식회사 마크로케어 항균 및 방부 활성을 갖는 식물 추출물을 포함하는 조성물 및 이의 용도

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JEON, W. K. ET AL.: "Study on the Anti-influenza Virus A type Activity of Citrus junos.", KOR. J. PHARMACOGN., vol. 31, no. 1, 2000, pages 82 - 86 *
LEE, J-H. ET AL.: "Screening of Antiviral Medicinal Plants against Avian Influenza Virus H1N1 for Food Safety.", KOREAN J. FOOD SCI. ANI. RESOUR., vol. 30, no. 2, 2010, pages 345 - 350 *
MOON, S-W. ET AL.: "Fermentation of Citrus unshiu Marc. and Functional Characteristics of the Fermented Products.", KOREAN J. FOOD SCI. TECHNOL., vol. 36, no. 4, 2004, pages 669 - 676, XP055238135 *

Also Published As

Publication number Publication date
KR20150134497A (ko) 2015-12-02
KR101706981B1 (ko) 2017-02-24

Similar Documents

Publication Publication Date Title
WO2012144754A2 (fr) Composition contenant un extrait de galla rhois présentant des effets inhibiteur de virus, ou un composé isolé à partir de celui-ci, comme ingrédient actif et ses utilisations
WO2017196006A1 (fr) Composition comprenant une bactérie lactique pour la prévention et le traitement de la vaginose et son utilisation
WO2013019049A1 (fr) Complexe comprenant des glycosides de stéviol ou de la racine de réglisse et matière faiblement soluble
WO2018062777A1 (fr) Composition d'amélioration de la force musculaire et de la masse musculaire comprenant un peptide de jus de soja dérivé de soja germé traité avec de l'eau de tangerine non mûre
WO2020218720A1 (fr) Composition pour la prévention ou le traitement de troubles musculaires ou l'amélioration de la fonction musculaire, contenant un extrait de leonurus japonicus ou de la léonurine
WO2015037778A1 (fr) Composition contenant un composé de lignane comme principe actif pour prévenir ou traiter un cancer
WO2014175543A1 (fr) Composition pour prévenir, soulager ou traiter la colite, contenant des extraits complexes
WO2017204547A1 (fr) Protéines polyvalentes de capture de virus et leur procédé de préparation
WO2012043949A1 (fr) Composition pour améliorer l'immunité contenant des composés représentés par les formules chimiques 1-8 ou l'extrait de sophora flavescens comme ingrédient actif
WO2021080297A1 (fr) Composition contenant un extrait de fleur d'onagre en tant que principe actif pour prévenir ou traiter l'obésité ou des syndromes métaboliques ainsi induits
WO2011099812A2 (fr) Composition de prévention ou de traitement de l'infection à rotavirus, contenant un extrait de réglisse
WO2020085826A1 (fr) Composition pour soulager une irritation de la peau induite par des facteurs de pollution environnementaux ou pour la protection de la peau, contenant comme principe actif un extrait de noix de muscade ou du macelignane
KR101828562B1 (ko) 귤나무속 열매 발효물을 유효성분으로 포함하는 항바이러스용 조성물
WO2015178700A1 (fr) Composition anti-virale comprenant un produit de la fermentation de fruits du genre citrus utilisé comme principe actif
WO2018106002A1 (fr) Composition pour la prévention et le traitement de la stérilité masculine, contenant une combinaison de composés comprenant un dérivé de flavonoïde et un dérivé d'iridoïde à titre de principe actif, et son utilisation
WO2010090498A2 (fr) Composition pharmaceutique et composition d'aliment naturel contenant un extrait de youngia denticulata, une fraction de celui-ci, ou un composé isolé à partir de celui-ci en tant que substance active pour améliorer la fonction hépatique
WO2009151236A2 (fr) Composition comprenant des extraits ou fractions de magnolia obovata thunb. utilisable pour le traitement et la prévention des affections inflammatoires
WO2022031151A1 (fr) Composition antivirale comprenant un extrait de fougère aigle orientale ou une fraction de celle-ci
WO2018221922A1 (fr) Composition pour la prévention et le traitement de maladies musculaires, contenant un extrait de coptidis rhizoma, et son utilisation
WO2022139529A1 (fr) Composition pour la prévention, l'amélioration ou le traitement de la gastrite ou de l'ulcère gastroduodénal comprenant un extrait de cinnamomum cassia, une fraction dudit extrait, un isolat de ladite fraction ou des composés isolés à partir de ladite fraction
WO2016190689A2 (fr) Composition permettant de prévenir, de soulager ou de traiter les maladies musculaires ou d'améliorer la fonction musculaire
WO2015105373A1 (fr) Composition pour la prévention ou le traitement de l'asthme, comprenant un extrait de l'e uonymus alatus ou une fraction de ce dernier
WO2018066969A1 (fr) Composition pharmaceutique comprenant de l'arazyme en tant que principe actif pour la prévention ou le traitement d'une maladie métabolique
WO2015111904A1 (fr) Composition pour la prévention ou le traitement d'une infection par le virus de la grippe comprenant un composant à base de curcuminoïde et un extrait de réglisse ou une fraction de celui-ci
KR20140106198A (ko) 귤나무속 열매 발효물을 유효성분으로 포함하는 항바이러스용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15795552

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15795552

Country of ref document: EP

Kind code of ref document: A1